ADC Therapeutics (ADCT) Receivables (2021 - 2026)
ADC Therapeutics (ADCT) posted Receivables of $31.0 million for Q1 2026, up 6.62% sequentially from $29.1 million in Q4 2025, and down 2.26% YoY from $31.8 million in Q1 2025.
ADC Therapeutics (ADCT) Receivables (2021 - 2026) Analysis & Trends
ADC Therapeutics has reported Receivables for 6 years, with the latest figure at $31.0 million in Q1 2026.
- Quarterly Receivables fell 2.26% year-over-year to $31.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $31.0 million (down 2.26% YoY) and the FY2025 annual result came in at $29.1 million, up 43.32% from the prior year.
- Receivables grew to $31.0 million in Q1 2026 per ADCT's latest filing, from $29.1 million in the prior quarter.
- Over five years, Receivables peaked at $73.8 million in Q4 2022 and troughed at $20.3 million in Q4 2024.
- A 5-year average of $28.2 million and a median of $25.1 million in 2023 frame the typical range for Receivables.
- The sharpest annual moves came in 2022 and 2023: Receivables soared 945.65% in 2022, then tumbled 65.87% in 2023.
- Over 5 years, Receivables stood at $73.8 million in 2022, then tumbled by 65.87% to $25.2 million in 2023, then fell by 19.32% to $20.3 million in 2024, then jumped by 43.32% to $29.1 million in 2025, then grew by 6.62% to $31.0 million in 2026.
- According to Business Quant data, Receivables over the past three periods registered $31.0 million, $29.1 million, and $22.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.41 Bn | 131.56 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 86.14 Bn | 78.15 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 65.52 Bn | 60.34 Bn | 1.37 Bn | 1.93 Bn |
| 4 | Moderna | 58.21 Bn | 53.07 Bn | 52.00 Mn | 160.00 Mn |
| 5 | BeOne Medicines | 42.15 Bn | 37.05 Bn | 1.53 Bn | 1.06 Bn |
| 6 | Alnylam Pharmaceuticals | 31.62 Bn | 28.31 Bn | 992.69 Mn | 912.74 Mn |
| 7 | BioNTech SE | 27.95 Bn | 9.56 Bn | 668.28 Mn | 1.09 Bn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 215.33 Mn |
| 9 | Royalty Pharma | 27.30 Bn | 26.46 Bn | - | - |
| 10 | ADC Therapeutics | 150.60 Mn | -68.51 Mn | 17.14 Mn | 28.04 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 28.04 Mn |
| Mar 31, 2026 | 31.05 Mn |
| Dec 31, 2025 | 29.12 Mn |
| Sep 30, 2025 | 22.92 Mn |
| Jun 30, 2025 | 26.18 Mn |
| Mar 31, 2025 | 31.76 Mn |
| Dec 31, 2024 | 20.32 Mn |
| Sep 30, 2024 | 24.03 Mn |
| Jun 30, 2024 | 22.87 Mn |
| Mar 31, 2024 | 23.19 Mn |
| Dec 31, 2023 | 25.18 Mn |
| Sep 30, 2023 | 23.30 Mn |
| Jun 30, 2023 | 25.35 Mn |
| Mar 31, 2023 | 25.10 Mn |
| Dec 31, 2022 | 73.78 Mn |
| Sep 30, 2022 | 24.95 Mn |
| Jun 30, 2022 | 21.74 Mn |
| Mar 31, 2022 | 27.78 Mn |
| Dec 31, 2021 | 31.01 Mn |
| Sep 30, 2021 | 15.90 Mn |